How I approach disease‐modifying therapy in children with sickle cell disease in an era of novel therapies

Abstract Finally,after decades of stagnation, the therapeutic landscape for sickle cell disease (SCD) is changing with an increasing number of novel therapeutics . Hydroxyurea remains the primary disease‐modifying therapy and, when started early in life with maintenance of an optimal dose, can reduce many SCD‐related complications. To complement hydroxyurea, there are a growing number of pharmacologic options with additional efforts focused on the development and optimization of curative therapies. Here, we review current treatment options and provide recommendations as to how to approach the treatment of children and adolescents within this evolving therapeutic landscape to allow for full and healthy lives.